ISTURISA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Israel, Italy, Japan, Lithuania, Poland, Romania, UK.

Active ingredients

The drug ISTURISA contains one active pharmaceutical ingredient (API):

1	Osilodrostat UNII Y6581YAW9V - OSILODROSTAT PHOSPHATE
	Osilodrostat is a cortisol synthesis inhibitor. It potently inhibits 11β-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In Cushing’s disease, the fall in plasma cortisol concentration also stimulates ACTH secretion, via the feedback mechanism which accelerates steroid biosynthesis.
	Read more about Osilodrostat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ISTURISA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
ISTURISA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H02CA02		H Systemic hormonal preparations, excl. Sex hormones and insulins → H02 Corticosteroids for systemic use → H02C Antiadrenal preparations → H02CA Anticorticosteroids
Discover more medicines within H02CA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1809671, 1809682, 1809693
FI	Lääkealan turvallisuus- ja kehittämiskeskus	062005, 578438, 598411
FR	Base de données publique des médicaments	61640118, 65986587, 67185086
GB	Medicines & Healthcare Products Regulatory Agency	396065, 396068, 396072
IL	מִשְׂרַד הַבְּרִיאוּת	9209, 9211
IT	Agenzia del Farmaco	048442014, 048442026, 048442038
JP	医薬品医療機器総合機構	2499015F1026, 2499015F2022
LT	Valstybinė vaistų kontrolės tarnyba	1089190, 1089191, 1089192
PL	Rejestru Produktów Leczniczych	100429970, 100429987, 100430000
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68432001, W68433001, W68434001
US	FDA, National Drug Code	55292-320, 55292-321, 55292-322